E Fund Management Co. Ltd. Has $888,000 Holdings in Insmed Incorporated (NASDAQ:INSM)

E Fund Management Co. Ltd. cut its stake in Insmed Incorporated (NASDAQ:INSM) by 11.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,858 shares of the biopharmaceutical company’s stock after selling 1,693 shares during the period. E Fund Management Co. Ltd.’s holdings in Insmed were worth $888,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of INSM. Vestal Point Capital LP raised its holdings in shares of Insmed by 113.3% in the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock worth $116,800,000 after buying an additional 850,000 shares in the last quarter. TimesSquare Capital Management LLC bought a new stake in Insmed during the 3rd quarter worth approximately $35,322,000. Victory Capital Management Inc. grew its position in Insmed by 209.9% during the 3rd quarter. Victory Capital Management Inc. now owns 455,959 shares of the biopharmaceutical company’s stock worth $33,285,000 after acquiring an additional 308,819 shares during the last quarter. Westfield Capital Management Co. LP bought a new stake in Insmed during the 3rd quarter worth approximately $18,377,000. Finally, Eventide Asset Management LLC grew its position in Insmed by 34.2% during the 3rd quarter. Eventide Asset Management LLC now owns 906,395 shares of the biopharmaceutical company’s stock worth $66,167,000 after acquiring an additional 231,210 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. UBS Group increased their price target on Insmed from $105.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday. HC Wainwright restated a “buy” rating and set a $90.00 price target on shares of Insmed in a research report on Friday, February 21st. JPMorgan Chase & Co. increased their price target on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Friday, February 7th. Guggenheim restated a “buy” rating and set a $101.00 price target on shares of Insmed in a research report on Tuesday, February 25th. Finally, Royal Bank of Canada started coverage on Insmed in a research report on Tuesday, February 25th. They issued an “outperform” rating and a $100.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $93.33.

Insider Buying and Selling

In related news, CFO Sara Bonstein sold 1,066 shares of the firm’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $63.72, for a total transaction of $67,925.52. Following the sale, the chief financial officer now owns 118,863 shares of the company’s stock, valued at approximately $7,573,950.36. This trade represents a 0.89 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO William Lewis sold 2,978 shares of the firm’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $63.36, for a total value of $188,686.08. Following the sale, the chief executive officer now directly owns 392,589 shares in the company, valued at $24,874,439.04. The trade was a 0.75 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 550,957 shares of company stock valued at $42,859,028. 4.60% of the stock is owned by company insiders.

Insmed Stock Down 0.2 %

NASDAQ:INSM opened at $74.89 on Friday. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $84.91. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $13.56 billion, a P/E ratio of -13.40 and a beta of 1.28. The stock’s fifty day simple moving average is $75.66 and its 200-day simple moving average is $73.83.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company had revenue of $104.44 million during the quarter, compared to the consensus estimate of $102.31 million. Equities research analysts expect that Insmed Incorporated will post -4.56 earnings per share for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.